該綜述是最早討論氫的生物學效應的論文,從中風的非藥物治療,談到氧氣和氫在中風治療中的作用價值.
Numerous clinical trials of thrombolytic and neuroprotective
drugs for stroke have been conducted over the last
2 decades. The NINDS trial of intravenous tissue plasminogen
activator remains the most notable success. Intra-arterial
thrombolysis appears promising, but in the absence of phase
III clinical trial data , this approach remains investigational.
Numerous pharmaceutical drugs targeting 1 or more cell
death pathways have failed to show efficacy. Despite failure,
these prior attempts have provided insights regarding critical
issues such as proper clinical trial design and the need for
more rigorous preclinical drug testing in order to improve the
translational leap from bench to bedside.
More recently, accumulating data suggest that “non-drug”
approaches toward stroke therapy might also provide new
opportunities in addition to more traditional pharmaceutical
therapies. As testimony to the growing importance of these
alternate and sometimes complementary methods, there has
been a proliferation of device trials, and the NINDS, through
its key 'Specialized Program of Translational Research in
Acute Stroke' [SPOTRIAS] initiative,1 has funded trials of
therapeutic hypothermia, caffeinol, and normobaric hyperoxia,
among others. Although this brief survey focuses on
emerging gas and device therapies for ischemic stroke, it
should be noted that several other 'non-drug' approaches,
including physiological strategies (eg, hypothermia, glucose
regulation), and natural agents (eg, albumin , magnesium),
continue to be tested in ongoing trials.
氫的科學研究 (5)
